AU2023257308A1 - Uses of farnesoid x receptor agonists - Google Patents

Uses of farnesoid x receptor agonists Download PDF

Info

Publication number
AU2023257308A1
AU2023257308A1 AU2023257308A AU2023257308A AU2023257308A1 AU 2023257308 A1 AU2023257308 A1 AU 2023257308A1 AU 2023257308 A AU2023257308 A AU 2023257308A AU 2023257308 A AU2023257308 A AU 2023257308A AU 2023257308 A1 AU2023257308 A1 AU 2023257308A1
Authority
AU
Australia
Prior art keywords
patient
compound
score
pharmaceutically acceptable
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023257308A
Other languages
English (en)
Inventor
Thomas CAPOZZA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercept Pharmaceuticals Inc
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of AU2023257308A1 publication Critical patent/AU2023257308A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2023257308A 2022-04-21 2023-04-21 Uses of farnesoid x receptor agonists Pending AU2023257308A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263333287P 2022-04-21 2022-04-21
US63/333,287 2022-04-21
US202263381752P 2022-10-31 2022-10-31
US63/381,752 2022-10-31
PCT/US2023/019448 WO2023205447A2 (en) 2022-04-21 2023-04-21 Uses of farnesoid x receptor agonists

Publications (1)

Publication Number Publication Date
AU2023257308A1 true AU2023257308A1 (en) 2024-10-10

Family

ID=88420596

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023257308A Pending AU2023257308A1 (en) 2022-04-21 2023-04-21 Uses of farnesoid x receptor agonists

Country Status (10)

Country Link
US (1) US20250288600A1 (https=)
EP (1) EP4511012A2 (https=)
JP (1) JP2025513289A (https=)
KR (1) KR20250006156A (https=)
CN (1) CN119136794A (https=)
AU (1) AU2023257308A1 (https=)
CA (1) CA3249500A1 (https=)
IL (1) IL315941A (https=)
MX (1) MX2024012966A (https=)
WO (1) WO2023205447A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4611888A1 (en) * 2022-10-31 2025-09-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017004708A2 (pt) * 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
ES2874682T3 (es) * 2016-03-11 2021-11-05 Intercept Pharmaceuticals Inc Derivados de 3-desoxi y composiciones farmacéuticas de los mismos
BR112019027458A2 (pt) * 2017-06-23 2020-07-07 Intercept Pharmaceuticals, Inc. métodos e intermediários para a preparação de derivados de ácidos biliares

Also Published As

Publication number Publication date
WO2023205447A3 (en) 2024-04-04
US20250288600A1 (en) 2025-09-18
CA3249500A1 (en) 2023-10-26
WO2023205447A2 (en) 2023-10-26
MX2024012966A (es) 2024-11-08
KR20250006156A (ko) 2025-01-10
EP4511012A2 (en) 2025-02-26
JP2025513289A (ja) 2025-04-24
IL315941A (en) 2024-11-01
CN119136794A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
Rautiainen et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three‐year randomized trial
Hirschfield et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid
Krones et al. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice
JP5094384B2 (ja) Ｆｘｒリガンドを使用する線維症の処置
JP2021063088A (ja) 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
Li et al. Bile acid G protein-coupled membrane receptor TGR5 modulates aquaporin 2–mediated water homeostasis
Debédat et al. Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?
JP2020147585A (ja) 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
Wang et al. Alteration in placental expression of bile acids transporters OATP1A2, OATP1B1, OATP1B3 in intrahepatic cholestasis of pregnancy
Felicetti et al. Cancer survivors: an expanding population with an increased cardiometabolic risk
US20220143003A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
Tang et al. Intrahepatic cholestasis of pregnancy: insights into pathogenesis and advances in omics studies
Polyzos et al. Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease
Kotsopoulos et al. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation
JP2024544538A (ja) ＴＨＲ－βアゴニストによる肝障害の治療
US20250288600A1 (en) Uses of farnesoid x receptor agonists
Uchiyama et al. Open-label, randomized, controlled, crossover trial on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan
Li et al. Effects of cisplatin and letrozole on surgically induced endometriosis and comparison of the two medications in a rat model
WO2024097247A1 (en) Uses of farnesoid x receptor agonists
Oleszczuk et al. Regenerative capacity differs between micro-and macrovesicular hepatic steatosis
Vieira et al. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study
US20230000832A1 (en) Use of neuropilin antagonists for the treatment of endometriosis
CN115605198B (zh) 脂肪性肝病的治疗药
Furini et al. Ketogenic state is able to improve testosterone serum levels-a meta-analytic approach
Lee et al. Changes in Insulin-like Growth Factor-1 Level in Patients with Sepsis and Septic Shock